ESR1 and breast cancer: Recent studies carried out through the analysis of ct-DNA released in the plasma of patients with ER+HER2- advanced BC identified putative predictive biomarkers of resistance to CDK4/6 inhibitors in ct-DNA, showing that ct-DNA analysis can be used for biomarker detection to inform genotyping-guided precision medicine [44].